Department of Psychiatry and Psychotherapy, and Interdisciplinary Tinnitus Clinic, University of Regensburg, 93053 Regensburg, Germany; email:
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres," Consejo Nacional de Investigaciones Científicas y Técnicas, 1428 Buenos Aires, Argentina.
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:291-313. doi: 10.1146/annurev-pharmtox-010818-021556. Epub 2018 Jul 25.
Tinnitus is a highly prevalent condition that is associated with hearing loss in most cases. In the absence of external stimuli, phantom perceptions of sounds emerge from alterations in neuronal activity within central auditory and nonauditory structures. Pioneering studies using lidocaine revealed that tinnitus is susceptible to pharmacological interventions. However, lidocaine is not effective in all patients, and no other drug has been identified with clear efficacy for the long-term treatment of tinnitus. In this review, we present recent advances in tinnitus research, including more detailed knowledge of its pathophysiology and involved neurotransmitter systems. Moreover, we summarize results from animal and clinical treatment studies as well as from studies that identified tinnitus as a side effect of pharmacological treatments. Finally, we focus on challenges in the development of pharmacological compounds for the treatment of tinnitus, namely the limitations of available animal models and of standardized clinical research methodologies.
耳鸣是一种高发疾病,多数情况下与听力损失相关。在没有外部刺激的情况下,中枢听觉和非听觉结构中的神经元活动改变会产生幻听。使用利多卡因的开创性研究表明,耳鸣易受到药物干预。然而,利多卡因并非对所有患者都有效,并且尚未发现其他药物对耳鸣的长期治疗具有明确疗效。在本次综述中,我们介绍了耳鸣研究的最新进展,包括对其病理生理学和涉及的神经递质系统的更详细了解。此外,我们还总结了动物和临床治疗研究以及将耳鸣确定为药物治疗副作用的研究结果。最后,我们重点讨论了用于治疗耳鸣的药物化合物开发所面临的挑战,即现有动物模型和标准化临床研究方法的局限性。
Annu Rev Pharmacol Toxicol. 2018-7-25
Neuroscientist. 2017-10-9
Hear Res. 2012-10-23
Brain Res. 2012-2-14
Curr Drug Targets. 2019
Nat Rev Neurol. 2016-3
Expert Opin Pharmacother. 2012-11-4
Biochem Biophys Rep. 2025-4-26
Eur Arch Otorhinolaryngol. 2025-1-17